As global markets face challenges such as trade policy uncertainties and inflation concerns, Asian tech stocks have been drawing attention for their potential to navigate these turbulent waters. In this environment, identifying promising high-growth tech stocks involves looking at companies with strong innovation capabilities and adaptability to shifting economic conditions.
Below we spotlight a couple of our favorites from our exclusive screener.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Everest Medicines Limited is a biopharmaceutical company focused on the discovery, license-in, development, and commercialization of therapies and vaccines for critical unmet medical needs in Greater China and other Asia Pacific markets, with a market cap of approximately HK$19.53 billion.
Operations: Everest Medicines Limited generates revenue primarily from its pharmaceuticals segment, amounting to CN¥418.55 million. The company is engaged in the discovery, license-in, development, and commercialization of therapies and vaccines targeting critical unmet medical needs across Greater China and other Asia Pacific regions.
Everest Medicines has demonstrated a robust entry into the high-growth tech sector in Asia, particularly with its innovative ulcerative colitis treatment, VELSIPITY®. The drug’s recent approval across multiple regions including Macau and Singapore underscores its potential, bolstered by strong Phase III trial results showing significant mucosal healing rates. With a revenue growth forecast at 33.4% annually and earnings expected to surge by 90.77% per year, Everest is positioning itself as a formidable player in addressing the escalating demand for advanced therapeutic solutions in Asia’s biotech landscape. This strategic expansion is further evidenced by its proactive engagements such as the recent special calls discussing mRNA vaccine developments and consistent regulatory successes that enhance its market presence and patient reach in crucial areas like China’s Greater Bay Area.
SEHK:1952 Revenue and Expenses Breakdown as at Mar 2025
Simply Wall St Growth Rating: ★★★★☆☆
Overview: OFILM Group Co., Ltd. engages in the manufacturing and sale of optic and optoelectronic products both domestically in China and internationally, with a market cap of approximately CN¥47.28 billion.
Operations: The company generates revenue primarily from the manufacturing of optics and optoelectronic components, amounting to approximately CN¥20.52 billion.
OFILM Group, transitioning into profitability this year, illustrates a dynamic shift in Asia’s high-tech landscape. With revenue growth outpacing the Chinese market at 15.6% annually and earnings expected to surge by 31.2% each year, OFILM is navigating its sector adeptly despite challenges like significant one-off gains of CN¥371.7M skewing recent financial results. The company’s strategic focus was evident in its latest shareholders meeting aimed at bolstering 2025 projections, reflecting an aggressive push towards sustaining innovations and market competitiveness in electronic components amidst evolving technological demands.
SZSE:002456 Revenue and Expenses Breakdown as at Mar 2025
Simply Wall St Growth Rating: ★★★★★★
Overview: Sharetronic Data Technology Co., Ltd. is a provider of wireless IoT products operating both in China and internationally, with a market capitalization of CN¥30.39 billion.
Operations: The company specializes in wireless IoT products, focusing on both domestic and international markets. With a market capitalization of CN¥30.39 billion, it leverages its expertise to cater to diverse technological needs across various regions.
Sharetronic Data Technology, recently added to major indices in the Shenzhen Stock Exchange, demonstrates robust growth prospects with a 26.2% annual revenue increase and a remarkable 29.1% expected earnings growth per year. This performance outstrips the broader Chinese tech sector’s average, positioning Sharetronic at the forefront of innovation and market expansion. The company’s recent shareholders meeting highlighted strategic initiatives aimed at expanding business scope and enhancing governance structures to support sustained growth and connectivity in high-tech industries across Asia.
SZSE:300857 Earnings and Revenue Growth as at Mar 2025
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SEHK:1952 SZSE:002456 and SZSE:300857.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Download
